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Establishing gene regulatory networks during differentiation or reprogramming requires
master or pioneer transcription factors (TFs) such as PU.1, a prototype master TF of
hematopoietic lineage differentiation. To systematically determine molecular features that
control its activity, here we analyze DNA-binding in vitro and genome-wide in vivo across
different cell types with native or ectopic PU.1 expression. Although PU.1, in contrast to
classical pioneer factors, is unable to access nucleosomal target sites in vitro, ectopic
induction of PU.1 leads to the extensive remodeling of chromatin and redistribution of partner
TFs. De novo chromatin access, stable binding, and redistribution of partner TFs both require
PU.1’s N-terminal acidic activation domain and its ability to recruit SWI/SNF remodeling
complexes, suggesting that the latter may collect and distribute co-associated TFs in con-
junction with the non-classical pioneer TF PU.1.
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Cellular differentiation requires so-called master or pio-neering transcription factors (TFs) to establish access toregulatory elements embedded in chromatin1. Similar to
the vast majority of TFs, they usually recognize specific DNA
motifs ranging from 6 to 12 base pairs (bp) in length, implying
the existence of roughly a million potential binding sites
throughout the genome2. How the actually bound sites, which
usually range in the thousands, are selected from the vast array of
putative binding sites is largely unknown.
The ETS family TF PU.1 (encoded by SPI1) is a well-studied
master regulator of the hematopoietic compartment and
is required for the generation of common lymphoid and
granulocyte-macrophage (MAC) progenitor cells, as well as later
stages of monocyte (MO)/MAC and B-cell development3. It
controls the expression of hundreds of genes that include growth
factor receptors, adhesion molecules, TFs, and signaling compo-
nents4, and is able to initiate myeloid gene expression programs
in heterologous cell types including T cells and fibroblasts5. The
ability of PU.1 to shape chromatin landscapes and re-program
cells and its role in regulating cell type-specific gene expression
make it a prototypic pioneer factor6. Yet, how this factor interacts
with chromatin to access its binding sites de novo to date has not
been elucidated.
The first genome-wide analyses of PU.1 occupancy observed
cell type-specific binding-site selection in murine MACs and B
cells7,8, as well as in human MOs and MO-derived MAC9. Cell
type-specific binding sites depended on the co-occurrence of
sequence motifs for other cell type-specific TFs, including
members of the C/EBP and AP-1 family TFs in human MO or
murine MAC, EGR2 in human MO-derived MAC, or E2A, EBF,
and OCT2 in B cells8,9. The exact mechanisms behind this
cooperativity between PU.1 and other TFs are not well under-
stood and may include direct protein–protein interactions,
interactions between TFs that are facilitated by DNA, DNA-
mediated interactions in the absence of TF interactions, and
indirect cooperativity involving competition between nucleo-
somes and TFs10. The requirement for TF cooperativity is
inversely correlated with motif affinity: high-affinity motifs are
frequently bound by PU.1 alone, whereas low-affinity motifs are
only bound when other factors co-bind nearby11. Known physical
interaction partners of PU.1 include general TFs such TFIID and
TBP (TATA-box binding protein), cell type-specific TFs such as
interferon regulatory factor 4 and 8 (IRF4 and IRF8), the proto-
oncogene c-Jun (JUN, a component of the AP-1 TF), and
early hematopoietic TFs such as GATA-binding protein 2
(GATA2) and runt-related TF1 (RUNX1)12–17. In early T cells,
PU.1–RUNX1 interactions lead to a redistribution of RUNX1
binding, highlighting the importance of TF interactions as well as
TF protein levels in binding-site selection18. These interactions,
however, do not explain how PU.1 exerts its presumed pioneering
role or how it selects its binding sites in chromatin in the
first place.
Here we systematically analyze the ability of PU.1 to access its
binding sites in vitro and in vivo. By profiling PU.1 binding
across a large atlas of hematopoietic cell types, we show that PU.1
only occupies a fraction of its potential binding sites, and that cell
type-specific binding is not exclusively explained by TF co-
association. In vitro studies further show that PU.1 binding to
DNA is subject to both epigenetic and chromatin constraints. It is
unable to bind CpG-methylated or nucleosome-bound DNA,
suggesting that PU.1 may not act as a classical pioneer factor,
which are defined by their ability to recognize their binding sites
in nucleosomal DNA. Despite these constraints, introduction of
PU.1 into heterologous model cell lines lacking endogenous PU.1
expression leads to extensive de novo remodeling of chromatin at
PU.1-binding sites and rapid initiation of a myeloid gene
expression program. Functional analysis of several mutant PU.1
variants indicates that efficient binding of PU.1 to de novo-
remodeled sites depends on the N-terminal acidic activation
domain (AAD), suggesting that the latter is strictly required for
accessing binding sites de novo. Further analyses including
in vivo proximity-dependent biotinylation (BioID) and co-
immunoprecipitation (CoIP) show that the N-terminal acidic
domain mediates the interactions of PU.1 with the SWI/SNF
family of chromatin remodeling complexes (BAF complex).
Hence, the ability of PU.1 to shape regulatory landscapes and to
act as a non-classic pioneer factor requires the AAD and its
interaction with SWI/SNF. The redistribution of partner TFs by
PU.1 also requires the SWI/SNF-interacting acidic domain, sug-
gesting that the remodeler complex may act as part of a hub to
collect and distribute co-associated TFs in a PU.1-dependent
manner.
Results
PU.1 binding across multiple cell types in vivo and in vitro. To
better understand what distinguishes PU.1-bound sequences from
unbound sequences, we first determined its DNA-binding profiles
across a large array of different cell types. PU.1 DNA-binding
maps have already been generated in a number of studies, but
comparative analyses were generally restricted to few cell types.
For a more comprehensive view of PU.1-binding patterns, we
collected publicly available occupancy data and generated several
additional PU.1 binding maps in various lymphoid and myeloid
cell lines, primary human cells and several MO-derived cell types
(Fig. 1a). Summaries of published and generated chromatin
immunoprecipitation sequencing (ChIP-seq) data are provided in
Supplementary Table 1 and Data File 1. With reference to a
previously defined PU.1 consensus sequence11, PU.1 binding
(defined by standard or stringent peak calling criteria) was only
detected at a fraction (<20%) of possible binding sites (Fig. 1b).
Bound sites were generally characterized by higher motif scores
(Fig. 1c). Cell type-restricted binding events (comprising 27% of
stringent peaks) were enriched for co-associated sequence motifs,
suggesting that combinatorial TF interactions support binding at
low-affinity sites (Supplementary Fig. 1d). Notably, high-affinity
sites (high motif log odds scores) are frequently bound across the
large majority of cell types (Supplementary Fig. 1e) and are
almost absent from the group of motifs showing no evidence of
ChIP-seq signals (Fig. 1c). Nevertheless, the observed dependency
on DNA sequence motifs (both for PU.1 and partner TFs) was
not mandatory, suggesting that PU.1 binding is controlled on
additional levels.
Obvious candidate mechanisms include the possible restriction
of PU.1 binding to DNA via the covalent modification of DNA
(e.g., DNA methylation) or via the competition with nucleo-
somes. To test this in vitro, we performed binding assays with
recombinant PU.1 on either (hydroxy-)methylated or
nucleosome-bound double-stranded DNA (dsDNA). DNA
(hydroxy-)methylation was found to interfere with PU.1 binding
when present close to the GGAA-core sequence, but not further
downstream, and only when occurring on the sense strand
(Fig. 1d). Of all sequences covered by the PU.1 consensus, only a
small fraction of about 20 K (10% of which are located in
promoters) contain a proximal CpG that might affect binding.
Nucleosomes also presented a barrier to PU.1 binding. Although
sites located around to the nucleosome dyad axis were not bound
at all, sites proximal to the nucleosome entry site were at least
partially accessible to PU.1 (Fig. 1e). This is in line with published
data for the highly homologous ETS domain of SPIB, which
showed a clear binding preference for linker and nucleosome
entry sites in the NCAP-SELEX assay19. These in vitro binding
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studies suggested that PU.1 alone is indeed restricted by both
DNA methylation and chromatin. Given the well-documented
pioneering role of this TF and its ability to access a large fraction
of high-affinity sites in vivo, PU.1 must be able to overcome
epigenetic and chromatin constraints at least to some extent.
Immediate consequences of de novo PU.1 expression. PU.1
occupancy maps across multiple cell types were useful to explore
cell type-specific binding preferences, but less informative
regarding rules of de novo binding-site selection. To better
understand how PU.1 selects binding sites in vivo and which
auxiliary factors may help to overcome epigenetic and chromatin
constraints, we established a system where PU.1 expression is
rapidly induced in a PU.1-negative acute lymphoblastic leukemia
cell line (CTV-1) using mRNA transfection (Fig. 2a, b). CTV-1
cells neither express endogenous PU.1 nor its related class III ETS
family members SPIB and SPIC (Fig. 2c), suggesting that recog-
nition sites of class III ETS factors may be “untouched” in these
cells. IRF4 and IRF8, which may form heterodimers with PU.1,
were also not detected in CTV-1 cells (Fig. 2c). At its peak, PU.1
protein expression levels in CTV-1 after mRNA transfection
exceeded those of natively high expressing cell types (such as
MO-derived dendritic cells (DCs) or THP-1 cell line; Supple-
mentary Fig. 2a).
In this model system, we observed de novo chromatin
remodeling and transcription (Fig. 2d, e) upon PU.1 expression.
Induced genes (measured 24 h after PU.1 mRNA transfection)
were associated with Gene Ontology (GO) terms such as myeloid
activation and differentiation (Fig. 2f), and expression levels of
these genes correlated with PU.1 expression across hematopoietic
cells types (Fig. 2g).
After establishing that transient PU.1 mRNA transfection in
CTV-1 cells affects relevant target genes, we examined the effects
of PU.1 expression on chromatin. Relative to control-transfected
cells (PU.1mut), we detected 45 K PU.1-binding sites (using
stringent peak calling criteria) by ChIP-seq. Of those, 80% or 94%
overlapped with stringent or standard peaks sets derived from all
natively PU.1-expressing cell types (in Fig. 1a), respectively. The
number of detected peaks was comparable to other highly PU.1-
expressing cell types (e.g., 51 K stringent peaks in DC, 35 K
stringent peaks in MO-derived MACs, or 63 K stringent peaks in
phorbol 12-myristate 13-acetate (PMA) and Vitamin D3-treated
THP-1 cells; peak counts of all samples are listed in Supplemen-
tary Table 1 and Data File 1). As shown in Fig. 3, clustering of
PU.1 peaks based on corresponding ATAC-seq data (a measure
of chromatin accessibility) separated PU.1 peaks into groups of
peaks with different degrees of accessibility before and after PU.1
induction and revealed extensive chromatin remodeling upon
PU.1 expression at PU.1 peak clusters 1–8, comprising the large
majority of PU.1-binding sites. PU.1 peak clusters with highly
remodeled sites (e.g., PU.1 peak clusters 6–8) were significantly
co-associated with the induced expression of neighboring genes,
either after a single PU.1 induction (short), or seven cycles of
PU.1 mRNA electroporation over 7 days (long).
To further characterize the properties of PU.1 peaks in clusters
defined by chromatin accessibility (Fig. 3), we first analyzed their
motif composition. We found that de novo-remodeled sites
generally associate with higher-affinity motifs compared with
PU.1-binding sites that were located in accessible chromatin prior
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Fig. 1 PU.1 occupancy in vivo and binding constraints in vitro. a Comparison of PU.1 ChIP-seq data across various human lymphoid and myeloid cell lines
(LCL and MCL, respectively) and primary cells (BC B cells, BDMC breast skin-derived mast cells, cMO classical MO, DC dendritic cells, HSPC
hematopoietic stem and progenitor cells, MAC, macrophages, MO monocytes, ncMO non-classical MO, NEU neutrophils) at an exemplary locus. For
replicated data sets (as indicated), averaged coverage tracks are shown. Total motif occurrences in standard and stringent peaks are summarized below
the tracks. b Fraction of PU.1 motifs residing in either standard or stringent PU.1 peaks (3.61 × 105 and 1.77 × 105, respectively) compared with all motif
occurrences (2.21 × 106) across the genome, motifs filtered for mappability (1.88 × 106), as well as motifs that showed no evidence of binding (<3 per 107
reads within 200 bp motif-centered window) across all samples (no signal, 3.48 × 105). c Distribution of motif scores across total occurrences,
mappability-filtered motifs, motifs in peaks, and no-signal motifs. d Microscale thermophoresis-derived dissociation constants (KD values, bars represent
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to PU.1 induction (Fig. 4a and Supplementary Fig. 2b). The
increasing chromatin accessibility through PU.1 peak clusters
1–14 was accompanied by a linear drop in average PU.1 motif log
odds scores and the increasing presence of nearby motifs for co-
associated TFs such as RUNX or GATA (Fig. 4b, c and
Supplementary Fig. 2c), which likely support the binding of
PU.1 at less-affine sites. In line with previous observations11, a
high degree of accessibility also correlated with evolutionary
conservation (Fig. 4d) and genomic annotation as promoters
(Fig. 4e), whereas de novo-remodeled sites often showed little
conservation across species and were mostly inter-/intragenic
(Fig. 4d, e). Although the above suggested an important role of
sequence-related features in the PU.1-binding-site selection,
modeling revealed that motif scores, conservation, and nearby
presence of co-associated motifs poorly discriminated PU.1-
bound and -unbound sites (Fig. 4f). Models including chromatin
accessibility in control cells showed a marginally improved
predictive power (Fig. 4f), suggesting that additional features
(such as chromatin structure or epigenetic modifications) must
have a significant impact on PU.1-binding-site selection. The best
predictor included chromatin accessibility data after PU.1
induction (Fig. 4f), which is in line with the ability of PU.1 to
increase accessibility at a large majority of binding sites.
Further analysis of chromatin accessibility data at single-
nucleotide resolution revealed common footprints across PU.1
motif-centered peaks in PU.1 peak clusters (examples are shown
in Fig. 4g). Notably, in PU.1 peak clusters with pre-accessible
chromatin (peak clusters 12–14), the footprints across PU.1
motifs pre-existed. The lack of change in accessibility, despite the
de novo binding of PU.1 suggests replacement or competition
with other (likely ETS family) TFs at these elements (Fig. 4g, right
histogram) rather than assisted loading as observed for GR20.
PU.1 induction also caused the rapid disappearance of ~3 K
accessible sites (Fig. 3, bottom panel), which were highly enriched
for consensus TF motifs (like RUNX, ETS, or GATA) that were
also identified in PU.1-induced accessible sites (Fig. 5a). The loss
of corresponding footprints at former and their gain at latter sites
(Fig. 5b–d) suggests the PU.1-induced redistribution of these
partner TFs, as recently observed for RUNX1 and SATB1 in early
T cells18.
To further confirm the marked impact of PU.1 induction on
chromatin landscapes, we analyzed two additional heterologous
cell lines (T-cell acute lymphoblastic leukemia-1 (TALL1) and the
hepatocellular carcinoma cell line HepG2). As observed in CTV-1
cells, PU.1 induction in either cell line caused the rapid
reorganization of chromatin landscapes, which showed similar
associations with either high-affinity motifs or the presence of cell
type-specific co-associated motifs, such as RUNX, IRF, and E2A
motifs in TALL1 cells, and FOXA1, HNF1, and HNF4 motifs in
HepG2 cells (Supplementary Fig. 3a–e). The predictive power of
individual features shown in Supplementary Fig. 3f was also
similar to CTV-1 cells, indicating similar constraints for PU.1
binding. Using published whole genome DNA methylation data
for HepG2 cells, we could additionally confirm the almost
exclusive binding of PU.1 to unmethylated GGAA-core sequences
(Supplementary Fig. 3g), as predicted from the in vitro binding
studies (shown in Fig. 1d). Redistribution of cell type-specific TFs
was also clearly evident in both cell types (Supplementary
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Fig. 3h–k), suggesting that PU.1 operates similarly in different
cell types.
Interaction among ETS family factors. As part of the motif
enrichment analysis (Fig. 4c), we noted that de novo-remodeled
PU.1 peaks frequently contained two (or more) PU.1 motifs.
Across peaks, these homotypic motif pairs were significantly
enriched (compared with non-bound motifs) in a range of 12–50
bp (Supplementary Fig. 4a), which resembles early findings of
clustered PU.1-binding sites in many myeloid-specific pro-
moters21. Notably, homotypic motif pairs were preferentially
found in the de novo-remodeled fraction of peaks (PU.1 peak
clusters 1–8). Their appearance correlated with the degree of
remodeling across PU.1 peak clusters (Supplementary Fig. 4b–f),
suggesting that PU.1 motif pairing could assist binding-site
selection. However, the motifs in pairs also showed significant
overlaps with consensus sequences for other ETS class family
members (Supplementary Fig. 4g), suggesting that de novo-
remodeled “homotypic” motif pairs are either bound by PU.1
alone or in combination with another ETS family member
expressed in CTV-1 cells.
As homotypic or heterotypic interactions of PU.1 may
influence binding-site selection, we asked whether and how the
distribution of other ETS factors would be affected by PU.1
expression and to which extent binding sites of PU.1 overlapped
with other ETS factors. We generated occupancy maps for two
prominent, representative ETS factors (FLI1, ETS1) in CTV-1
cells before and after PU.1 expression (an exemplary locus is
shown in Fig. 6a). Both factors share an almost identical ETS class
1a motif, which was clearly different from the PU.1 consensus site
(Fig. 6b, c). Correspondingly, the largest fraction of FLI1 and
ETS1 target sites overlapped (Fig. 6d), suggesting that they
compete for the majority of genomic binding sites. The small
fraction of ETS1-specific peaks was primarily associated with two
co-associated motifs (ZNF143 and a composite ETS:RUNX motif,
see Supplementary Fig. 5a, b), indicating that corresponding TFs
may favor ETS1 at these sites.
The induction of PU.1 had a major impact on the genomic
distribution of FLI1 and ETS1 in CTV-1 cells (Fig. 6e, f and
Supplementary Fig. 5c). As already indicated by the footprints
across PU.1 motifs observed at pre-accessible PU.1-binding sites
(as shown for PU.1 peak cluster 13 in Fig. 4g), PU.1 joined the
competition of ETS factors at a large fraction of pre-existing ETS-
binding sites (across clusters 9–14). Correspondingly, the ChIP-
seq coverage of ETS1 and FLI1 at pre-accessible PU.1-binding
sites was reduced after PU.1 induction (Supplementary Fig. 5d).
Likewise, both ETS factors joined PU.1 at a major subset of de
novo-remodeled fraction of peaks (Fig. 6e, f and Supplementary
Fig. 5c, f) across PU.1 peak clusters 1–8. Motif scores of ETS
factors and PU.1 at their binding sites showed an inverse
correlation across de novo-remodeled PU.1 peak clusters 1–8
(Fig. 4a and 6g, and Supplementary Fig. 5e). The predicted
recognition motif resembled the ETS motif at PU.1-binding sites
co-bound by ETS factors (both at single and paired motif sites),
whereas sites without evidence of ETS binding resembled the
PU.1 consensus motif (Supplementary Fig. 5g). This suggests that
the ETS factor distribution is driven at least in part by motif
affinities of individual factors. At sites bound by PU.1 alone,
chromatin accessibility changes were limited, regardless of the
presence of single or paired sites (Supplementary Fig. 5h),
suggesting that binding at these motif pairs is likely restricted to a
single position. At present, we cannot say whether the recruit-
ment of ETS factors (or other partner factors) to de novo-
remodeled sites actively contributes to the process of remodeling
or whether it stabilizes the accessible space between two
nucleosomes created in the course of PU.1 binding. Nevertheless,
it is clear that at these sites, PU.1 is required to allow for ETS
factor binding, which is not observed in the absence of PU.1.
In line with the redistribution of other partner TFs (as shown
in Fig. 5a–d), the binding of ETS1 and FLI1 was also reduced at
the disappearing ~3 K sites that were accessible prior to PU.1
induction (Fig. 6e, bottom panel), further corroborating the
ability of PU.1 to redistribute other TFs.
PU.1 domains and interactors required for de novo binding.
Next, we sought to characterize the mechanism underlying PU.1’s
ability to change chromatin accessibility and redistribute other
TFs across the genome. Hypothesizing that specific interactions of
PU.1 with other proteins are involved in these changes, we tested
the effects of deleting different known protein–protein interaction
PU
.1
1 kb
Cl
us
te
rs
R
em
-In
de
x
1.4
2.4
2.0
3.2
3.6
6.1
5.7
5.0
1.2
1.7
1.2
1.5
1.1
1.0
45
 K
 P
U.
1 
bi
nd
in
g 
sit
es
 
m
u
t
PU
.1
m
u
t
PU
.1
m
u
t
FlagPU.1
(n = 3)
ATAC
(n = 3)
H3K27ac
(n = 3)
mRNA S
ho
rt
(n 
=
 
2)
Lo
ng
(n 
=
 
1)
Effect on
transcr. 
***
**
***
******
****
**
***
0
25
0
15
0
15
Coverage
13
11
12
10
9
14
8
7
6
5
4
3
2
1
3 
K 
le
ss
o
pe
n 
sit
es
Fig. 3 PU.1-induced changes in chromatin accessibility. The distribution of
average PU.1 ChIP-seq, ATAC-seq, and H3K27ac ChIP-seq signals of PU.1
vs. PU.1mut mRNA-transfected cells 8 h after electroporation are plotted
across 1 kb windows and 45 K PU.1-binding sites (top panel) or 3 K regions
that lost accessibility after PU.1 induction (bottom panel) in CTV-1 cells.
PU.1 peaks are ordered according to K-means clustering of peak-centered
ATAC-seq signals. PU.1 peak clusters are indicated by the color bar on the
right, along with the average remodeling index (Rem-Index) of each cluster.
The asterisks on the right indicates the significant induction of mRNA
expression across genes associated with PU.1 peaks in the indicated peak
cluster (***P < 0.001; **P < 0.01; *P < 0.05; paired Wilcoxon’s test) in PU.1-
expressing CTV-1 cells. The coloring of PU.1 peak clusters is kept consistent
in all following analyses based on the clustering. Source data are provided
as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13960-2 ARTICLE
NATURE COMMUNICATIONS | (2020)11:402 | https://doi.org/10.1038/s41467-019-13960-2 | www.nature.com/naturecommunications 5
domains of PU.1 on its ability to access chromatin de novo. To
this end, we generated PU.1 expression constructs devoid of each
one or all of the acidic (A), glutamine-rich (Q), and PEST (P)
domains, and tested them in our model compared with wild-type
PU.1 (Fig. 7a). All mutant proteins were expressed and translo-
cated to the nucleus as expected (Fig. 7b). Detected peak sets of
PU.1 mutants generally represented subsets of the wild-type and
in three of four cases, binding profiles differed significantly from
wild-type PU.1 (Fig. 7c, d). Most pronounced changes in peak
coverage were observed for the isolated ETS domain (ΔAQP, 77%
of wild-type PU.1 peaks showed significantly reduced signals) and
the mutant lacking the acidic domain (ΔA, 72% of wild-type PU.1
peaks showed significantly reduced signals), followed by the less-
affected mutant lacking the glutamine-rich domain (ΔQ, 52% of
wild-type PU.1 peaks showed significantly reduced signals),
which partially resembled a lower dose of PU.1 (15% PU.1, 29%
of wild-type PU.1 peaks showed significantly reduced signals).
The ΔP mutant did not reveal significantly altered binding pat-
terns. Interestingly, binding profiles of ΔA and ΔQ mutants were
particularly different at highly remodeled clusters (Fig. 7e, clusters
7/8), suggesting that the ΔA mutant may specifically lack remo-
deling capacity.
To identify interaction partners of PU.1 that may explain the
observed effect of PU.1 mutant proteins, we adapted the BioID
approach22 to biotinylate and identify candidate interacting
proteins in the proximity of PU.1 (Fig. 8a). We initially validated
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that the BirA fusion constructs were expressed, functional, and
recruited to the same locations compared with wild-type
constructs (Supplementary Fig. 6a–c). BioID experiments in
CTV-1 cells transfected with wild-type PU.1-BirA and BirA
carrying a nuclear localization sequence (NLS) as control (NLS-
BirA) followed by mass spectrometry of biotin-ligated proteins
revealed significant enrichment of proteins associated with the
SWI/SNF complex (Fig. 8b, c) in the neighborhood of PU.1. We
obtained similar results with constitutively PU.1-expressing THP-
1 and K-562 cells, confirming that this was not confined to CTV-
1 cells (Supplementary Fig. 6d). Performing BioID analysis with
the ΔA and ΔQ deletion mutants, we found that the ΔA mutant,
but not the ΔQ mutant, specifically lost proximity to the SWI/
SNF remodeling complex relative to full-length PU.1 (Fig. 8d).
The specific interaction between PU.1 and SWI/SNF was also
observed in CoIP experiments. Focusing on the central ATP-
dependent chromatin remodeler SMARCA4 (BRG1), we
observed its specific interaction with PU.1 independent of the
presence or absence of DNA (Supplementary Fig. 6e), and both in
FLAG-PU.1 and BRG1 CoIPs (Fig. 8e and Supplementary Fig. 6f).
We also detected two additional SWI/SNF components (ARID2
and SMARCE1) in CoIP westerns (Supplementary Fig. 6g, h).
However, we could not detect FLI1 or LDB1 in CoIPs, suggesting
that, although being proximal to PU.1, they do not interact with
PU.1 directly, or that the interaction is not stable during CoIP.
Although SWI/SNF components were reproducibly detected in
CoIPs with wild-type PU.1, these interactions were slightly
reduced with the ΔQ mutant and strongly reduced or absent with
the ΔA mutant (Fig. 8e and Supplementary Fig. 6f-h).
We further confirmed that PU.1 interacts with SWI/SNF by
blocking experiments and ChIP-seq of SMARCA4 (BRG1) in
CTV-1 cells after induction of PU.1 or its ΔQ and ΔA mutants.
Inhibition of SMARCA4 (BRG1) led to a dose-dependent
reduction of PU.1 binding across the entire genome (Supple-
mentary Fig. 6i, j), suggesting that its inactivation may have a
general effect on TF binding. ChIP-seq experiments after
induction of PU.1 clearly demonstrated the recruitment of
SMARCA4 (BRG1) to PU.1-remodeled sites (Fig. 8f, g). As
exemplified by the GSN locus (Fig. 8f) and across all PU.1-
binding sites (Fig. 8g), the ΔQ mutant retained some of the
remodeling capacity of wild-type PU.1. However, the ΔA mutant,
although retaining some of its binding capacity, was neither able
to alter chromatin accessibility nor did it recruit SMARCA4
(BRG1) to the otherwise de novo-remodeled sites.
In addition, as shown in the bottom panel of Fig. 8g, the
redistribution of partner TFs was disabled in the ΔA mutant.
Notably, the PU.1-induced redistribution of partner factors also
included SMARCA4 (BRG1), which was depleted upon PU.1
induction at the ~3 K sites that lose accessibility. Upon induction
of the ΔA mutant, however, the remodeler remained at
those sites.
Discussion
The present work provides a detailed analysis of mechanisms
allowing the master regulator PU.1 to shape regulatory land-
scapes. We show that its N-terminal AAD interacts with the SWI/
SNF remodeling complex and that this interface is required for
PU.1 to access and remodel chromatin de novo. However, despite
its potentially strong impact on chromatin landscapes, PU.1 is not
a pioneer factor in its classical definition. In vivo PU.1-binding
profiles as well as in vitro binding studies suggest that PU.1
binding is constrained by chromatin and epigenetic mechanisms,
in particular by nucleosome positioning. Hence, it likely initiates
remodeling primarily at those binding sites (and prepares them
for other factors) that it can access. Given that even classical
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pioneer factors, which are able to bind nucleosomal target sites,
depend on epigenetic and chromatin landscapes23,24, we propose
a new class of non-classical pioneer factors, such as PU.1, which
share pioneering functions with classical factors but lack the
ability to access nucleosome-bound target sites.
A prerequisite for pioneering is the ability to recruit remo-
deling complexes. Our data show that the N-terminal AAD of
PU.1, which was originally defined as an activation domain using
reporter assays25 mediates the interaction with SWI/SNF. This is
in concordance with earlier work demonstrating that AADs of
other TFs in yeast, including VP16, Gcn4, Swi5, and Hap4,
interacted directly with purified SWI/SNF complex and with the
SWI/SNF complex in whole-cell extracts26. There is also abun-
dant evidence for a crucial role of SWI/SNF remodeling com-
plexes in the establishment and maintenance of lineage-specific
enhancers27–29, and their recruitment to target loci is believed to
require interaction with DNA-associated TFs. Our work clearly
shows that PU.1 is one of those factors that recruits SWI/SNF to
its binding sites. This will allow PU.1 to fulfil its role as a master
regulator and to participate in the establishment of enhancers
across many hematopoietic cell types.
In a given cell type, PU.1 usually occupies a small fraction
(5–10%, depending on the statistical stringency of peak calling) of
its potential binding sites. Previous work indicated that PU.1-
binding-site selection in individual cell types depends on its
expression level and the cell type-specific mix of partner TFs7–9.
The current work suggests that these factors only partially explain
PU.1-binding-site selection in individual cell types. In line with
chromatin and epigenetic constraints observed in vitro, PU.1
cannot access all high-affinity sites in all cell types, despite its
ability to recruit the remodeling machinery. The current work
suggests that its pioneering role depends on cell type-specific
chromatin structures, and that the ability of PU.1 to establish
novel regulatory elements is likely restricted to accessible binding
sites. According to our in vitro experiments, the latter may lack
DNA methylation and locate to nucleosomal linker regions or
sequences proximal to nucleosome entry sites. Although detailed
nucleosome (and corresponding DNA methylation) maps will be
required to prove this model, a restricted pioneering role of PU.1
perfectly explains the diverse and manifold PU.1 binding patterns
observed across cell types. The frequent observation of shallow
ChIP-seq signals (below peak detection) could be owed to the fact
that nucleosome positions are not fixed across the large part of
the genome and rarely synchronized across populations of cell
types, which may create ample opportunities for PU.1 to bind
particular recognition sequences in a (variable) sub-fraction of
cells, where these sites are accessible.
Interestingly, the expression of PU.1 not only affected reg-
ulatory elements containing PU.1-binding sites. Hosokawa et al.18
recently showed that PU.1 regulates gene expression in early T-
cell development both by recruiting TFs RUNX1 and SATB1 to
its own binding sites and by depleting them from the binding sites
that they occupied in the absence of PU.118. Our data extend their
model to PU.1 partner proteins in general and implicate SWI/
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SNF remodelers in the process of TF redistribution. Based on our
footprinting and ChIP-seq analyses, we observe the same type of
factor redistribution in all three cell systems (CTV-1, TALL1, and
HepG2) studied here. The PU.1-induced redirection primarily
affected TFs occupying lineage-specific cis-modules, such as
RUNX1 and GATA-family factors in T-cell lines and HNF- and
FOXA-family factors in the liver cell line. Interestingly, the
redistribution of partner TFs required the acidic domain of PU.1,
which is not required for direct protein–protein interactions with
RUNX1, GATA-, AP1-, or C/EBP-family factors14–17. Hence, the
direct binding to partner proteins may not be sufficient for PU.1
to sequester partner proteins. The fact that the N-terminal acidic
domain of PU.1 interacts with SWI/SNF implicates remodeling
complexes in the redirection of partner proteins. The decom-
missioning of TF-bound cis-modules after PU.1 induction could
be mediated through the reallocation of limiting SWI/SNF
remodeling complexes by PU.1, which are generally required to
maintain the accessible state of regulatory elements such as
lineage-specific enhancers27–30. As many of the identified PU.1
partner proteins have already previously been shown to interact
with components of SWI/SNF remodeling complexes31–34, the
latter may act as part of a hub increasing the probability of co-
binding of PU.1 partner proteins at de novo-remodeled binding
sites. In conclusion, our systematic analysis of de novo TF
binding reveals important mechanistic details and provides more
comprehensive understanding of a master regulator that shapes
regulatory landscapes during hematopoiesis, has known repro-
gramming capabilities, but is different from “classical” pioneer
factors.
Methods
Cell culture. CTV-1 (DSMZ: #ACC 40), HepG2 (DSMZ: #ACC 180), K-562 (DSMZ:
#ACC 10), TALL1 (DSMZ: #ACC 521), and THP-1 cells (DSMZ: #ACC 16) were
grown in RPMI 1640 (Gibco) routinely supplemented with 2mM L-glutamine
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shown across ATAC-seq-derived PU.1 peak clusters (introduced in Fig. 3). b–e Source data are provided as a Source Data file.
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(Biochrom), 1mM sodium pyruvate (Sigma), 50 Uml−1 penicillin/streptomycin, 0.4×
vitamins (Sigma), 1× non-essential amino acids (Sigma), 50 μM b-mercaptoethanol
(Gibco), and 10% or 15% (TALL1) heat-inactivated fetal calf serum (FCS) (Gibco) at
37 °C, 5% CO2, 95% humidity. Cells were split every 2–3 days and resuspended in
fresh medium. Adherent HepG2 cells were detached using 1× Trypsin-EDTA
(Thermo Fisher Scientific). After 20 passages, cells were discarded and a new batch of
cells was used. For differentiation of THP-1 cells into MAC-like cells PMA (10−8M;
Calbiochem) and 1,25-dihydroxyvitamin D3 (VD3, 10−7M; Sigma) were added, cells
were incubated for 3 days at 37 °C, 5% CO2, 95% humidity, and adherent cells were
detached using Accutase solution (Sigma). Collection of blood cells from healthy
donors was performed in compliance with the Helsinki Declaration. All donors signed
an informed consent. The leukapheresis procedure and subsequent purification of
hematopoietic cell types were approved by the local ethical committee (reference
number 12-101-0260). Separation of peripheral blood cell types and in vitro
differentiation of MOs into MACs or DCs were performed as described
previously9,35,36. B cells were purified as described37. Neutrophils were purified from
whole blood after lysis of erythrocytes with ACK (Ammonium-Chloride-Potassium)
lysis buffer (5ml per ml blood of 155mM NH4Cl, 100mM KHCO3, 0.1mM EDTA)
and purified by fluorescence-activated cell sorting (FACS) based on size and granu-
larity. Human mast cells were purified from the skin that was obtained from cosmetic
breast-reduction surgeries38 with informed consent of the patients. Mast cell pre-
parations were performed in compliance with the Helsinki Declaration and were
approved by the ethics committee of the Charité Universitätsmedizin Berlin (reference
number EA1/204/10).
Transfection of in vitro transcribed mRNA. Synthetic DNA templates (gBlocks)
for wild-type PU.1, it’s mutated version, all PU.1-deletion mutants, and all BirA*
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Fig. 8 Identification of PU.1 proximal proteins using BioID. a Schematic of the experimental setup. b Volcano plot illustrating proteins significantly
enriched in PU.1-BirA-mRNA-transfected CTV-1 cells compared with NLS-BirA-mRNA-transfected control cells. Blue dots represent proteins with FDR <
0.05 and log fold change (logFC) > 2. Only PU.1-specific proteins of GO terms for chromatin organization and interesting transcriptional regulators are
highlighted. c STRING analysis illustrating the functional protein association network. The network view summarizes predicted associations for proteins
significantly enriched in the PU.1-BioID. The network nodes represent the proteins, the edges represent predicted functional associations. Only connected
nodes are shown. d Dot plots showing the enrichment of peptides (ratios of log2-transformed normalized iBAQ values) representing the indicated SWI/
SNF components (PU.1/SPI1 is shown as a control) in BioIDs from PU.1-BirA vs. NLS-BirA (control), ΔQ-BirA, or ΔA-BirA-mRNA-transfected CTV-1 cells
(***P < 0.001; **P < 0.01; *P < 0.05; paired t-test, permutation-based correction). e Immunoblotting of αFLAG mAb immunoprecipitations (5 h after
electroporation, IP 5 h), along with corresponding input lysates of control (mock), PU.1, ΔQ, ΔA, and BirA-mRNA-transfected cells using the indicated
antibodies. f IGV genome browser tracks for the GSN locus showing SMARCA4 (BRG1) and PU.1 ChIP-seq, as well as ATAC-seq coverage in control
(mutPU.1, gray–green)-, PU.1 (blue)-, ΔQ mutant (green)-, and ΔA mutant (lightbrown)-expressing cells. g Distribution of the PU.1 ChIP-seq, ATAC-seq
signal, and SMARCA4 (BRG1) ChIP-seq signals in control (mutPU.1), PU.1, ΔQ, and ΔA mRNA-transfected cells across the 45 K clustered PU.1-binding
sites, as well as the disappearing ~3 K sites that were accessible prior to PU.1 induction. b–e, g Source data are provided as a Source Data file.
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fusion constructs for proximity-dependent interaction analysis were ordered at
IDT (Integrated DNA Technologies). Sequences are provided in Supplementary
Data File 2. Constructs were assembled into a BamHI and XbaI (NEB)-linearized
T7 promoter-containing vector (pEF6; Invitrogen) either using T4 DNA ligase
(Promega) or the NEBuilder HiFi DNA Assembly Master Mix (NEB). SfuI (Roche)
linearized plasmids were phenol:chloroform-purified and were used to generate
in vitro transcribed (IVT) mRNA with the mMESSAGE mMACHINE T7 Ultra Kit
(Ambion) according to the manufacturer’s instructions. IVT mRNA was purified
with the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.
For electroporations, routinely 3 × 106 cells were pelleted and washed once at room
temperature with phenol red-free RPMI 1640 (Gibco) and once with phenol red-
free Opti-MEM I (Gibco). Cell number was scaled-up as needed. Cells were elec-
troporated in 200 µl phenol red-free Opti-MEM I in a 4 mm cuvette using a Gene
Pulser Xcell (Bio-Rad) with a rectangular pulse of 400 V and 5 ms duration, usually
delivering 3 µg PU.1 IVT mRNA. IVT mRNA amounts of additional constructs
were calculated according to their size relative to PU.1 (ΔA 2.3 µg, ΔQ 2.6 µg, ΔP
2.6 µg, and ΔAQP 1.5 µg of IVT mRNA). Immediately after electroporation, the
cell suspension was transferred into pre-warmed culture medium (1 × 106/ml) and
cultured at 37 °C, 5% CO2, and 95% humidity for the indicated times. Electro-
porated cells were 85–95% viable as analyzed by DAPI (4′,6-diamidino-2-pheny-
lindole) staining and corresponding FACS analyses. Expression levels of
overexpressed proteins were determined by immunoblotting 8 h after transfection.
To study the effect of long-term PU.1 expression in terms of induced gene
expression changes in the heterologous CTV-1 cell line, cells were subjected to
seven cycles of PU.1 and PU.1mut mRNA transfection, respectively, for 7
consecutive days prior to total RNA isolation and transcriptome analyses
(Fig. 3, long).
Co-immunoprecipitation. PU.1 protein containing complexes were isolated by
affinity purification as previously described by Hosokawa et al.18, with slight
modifications. In brief, 10 × 106 CTV-1 cells were mock transfected (electropora-
tion without RNA) or transfected with 10 µg of PU.1 mRNA, 8.6 µg of ΔQ mRNA,
7.6 µg of ΔA mRNA, and 7.6 µg of NLS-BirA as additional control. Transfected
cells were incubated for 5 h at 37 °C, 5% CO2, 95% humidity prior to cell lysis using
IP buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Tween-20,
1 mM EDTA, 10 mM NaF, 1× protease inhibitor cocktail). Cells were solubilized
on ice for 30 min with gentle shaking and sonicated three times for 10 s followed by
30 s rest on ice on a Branson Sonifier 250 (constant duty cycle, output control 2).
Insoluble material was removed by centrifugation and the protein concentration of
each lysate was assessed using the Qubit Protein Assay Kit. Where indicated,
lysates were additionally treated with 250 U of benzonase (Sigma) for 30 min at
37 °C prior to immunoprecipitation to digest genomic DNA. Ten micrograms of
each lysate were saved as input control, before a pre-clearing step with mouse IgG-
Agarose (Sigma) was performed for 1 h at 4 °C on a rotating wheel. Pre-cleared
protein extracts were subjected to immunoprecipitation with anti-FLAG M2
agarose (Sigma) overnight at 4 °C on a rotating wheel. Enriched complexes were
eluted from the agarose using 3×FLAG peptide (Sigma) and protein concentrations
were assessed using the Qubit Protein assay Kit. Ten micrograms of the immu-
nocomplexes were separated together with the corresponding input samples by
SDS-polyacrylamide gel electrophoresis (PAGE) on 10% pre-cast polyacrylamide
gels (Bio-Rad). Immunoblotting was performed as described below, using the
following antibodies as indicated: anti-ARID2 (sc-166117, Santa Cruz, 1:100), anti-
BRG1 (ab110641, Abcam, 1:2000), anti-FLAG M2 (F3165, Sigma, 1:5000), anti-
Histone H3 (ab1791, Abcam, 1:2000), anti-PU.1 (sc-352×, Santa Cruz, 1:5000),
anti-SMARCE1 (ab131328, Abcam, 1:500), anti-FLI1 (ab15289, Abcam, 1:1000),
and anti-LDB1 (ab96799, Abcam, 1:1000).
Reverse CoIP of BRG1-containing complexes were performed using the
Dynabeads antibody coupling kit provided by Thermo Fisher Scientific. The
anti-BRG1 (ab110641, Abcam) antibody was covalently coupled to Dynabeads
according to the manufacturer’s instructions and 10 × 106 transfected CTV-1
cells were used for the IP experiments. Cells were lysed in Dyna-IP buffer
(20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1×
protease inhibitor cocktail) and solubilized on ice for 30 min with gentle shaking.
After three rounds of sonication, 10 s each followed by 30 s rest on ice using a
Branson Sonifier 250 (constant duty cycle, output control 2), insoluble material
was removed by centrifugation. The protein concentration of each lysate was
assessed using the Qubit Protein Assay Kit and 10 µg of each lysate was saved as
input control. Lysates were incubated with anti-BRG1-coupled Dynabeads for
1.5 h at room temperature on a rotating wheel and washed on a magnet three
times each with phosphate-buffered saline (PBS) including Tween-20 (0.02%)
and ultrapure water, respectively. For elution of protein complexes, 50 µl 2× SDS
sample buffer without 2-mercaptoethanol was added to the beads, before the
beads were incubated at 95 °C for 10 min. Supernatants were collected on a
magnetic rack and mixed with 2.5 µl 2-mercaptoethanol each. Twenty
microliters of the immunocomplexes were separated together with the
corresponding input samples by SDS-PAGE on 10% pre-cast polyacrylamide
gels (Bio-Rad). Immunoblotting was performed as described below, using the
following antibodies as indicated: anti-BRG1 (ab110641, Abcam, 1:2000), anti-
FLAG M2 (F3165, Sigma, 1:2000), anti-PU.1 (sc-352×, Santa Cruz, 1:5000), and
anti-Histone H3 (ab1791, Abcam, 1:2000).
Immunoblotting. Immunoblotting of whole-cell extracts was performed as
described previously39 and all protein lysates were collected 8 h after transfection.
Nuclear extracts were prepared using ice-cold hypotonic sucrose buffer (1% Triton
X-100, 320 mM Sucrose, 10 mM Hepes pH 7.5, 5 mM MgCl2, 1 mM phe-
nylmethylsulfonyl fluoride (PMSF), 1× protease inhibitor cocktail, 1× phosphatase
inhibitor cocktail). Cells were solubilized on ice with hypotonic buffer using a tissue
grinder (Sigma) with ten strokes per sample. After centrifugation, the supernatant
was saved as cytoplasmic fraction and cell nuclei were washed twice with ice-cold
sucrose wash buffer (320 mM, 10 mM Hepes pH 7.5, 5 mM MgCl2, 1 mM PMSF,
1× protease inhibitor cocktail, 1× phosphatase inhibitor cocktail). To shear the
DNA, nuclei were resuspended in ice-cold nuclear sonication buffer (50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA pH 8.0, 10% glycerol, 1 mM PMSF, 1×
protease inhibitor cocktail, 1× phosphatase inhibitor cocktail) and sonicated twice
for 10 s with a rest of 30 s on ice using a Branson 250 sonifier. Sheared DNA was
removed by incubation with 250 U of benzonase (Sigma) for 30 min on ice, fol-
lowed by centrifugation. Nuclear extracts were transferred into fresh tubes and the
protein concentration of cytoplasmic and nuclear lysates was determined using the
Qubit Protein Assay Kit (Thermo Fisher Scientific). Usually, 15 µg of each fraction
were incubated at 95 °C for 10 min in 2× SDS buffer, separated by SDS-PAGE and
were transferred to polyvinylidene difluoride membranes (Merck). Immunoblots
were probed with the following antibodies as indicated: anti-Actin (A2066, Sigma,
1:2000), anti-Histone H3 (ab1791, Abcam, 1:2000), anti-FLAG M2 (F3165, Sigma,
1:2000), or anti-PU.1 (sc-352, Santa Cruz, 1:2500).
Gelshift assays. Nucleosomes for nucleosome-PU.1 interaction assays were
assembled as described40. DNA fragments for assembly were produced via PCR
from gBlocks ordered from IDT. Corresponding sequences are listed in Supple-
mentary Table 2 and PCR primer sequences are provided in Supplementary
Table 3. The DNA templates consist of a stretch of D.m. HSP70 promoter followed
by the 601 nucleosome-positioning sequence (NPS). The PU.1 high-affinity
binding motif 5′-CACTTCCTCTTT-3′11 was inserted at varying distances to the
nucleosome border. Forward primers for DNA fragments with the PU.1-binding
motif were labeled with Cy5. Forward primers for control fragments without a
PU.1-binding motif were labeled with Cy3. Recombinant human PU.1 was
expressed in Escherichia coli (Rosetta2(DE3)pLysS) with C-terminal FLAG- and N-
terminal His-tags. The protein was natively purified using the His-tag on a Ni-NTA
resin (Qiagen) via a gravity flow column. Protein concentration was determined via
Bradford assay in comparison with bovine serum albumin (BSA) calibration
solutions. Free DNA (50 nM) or nucleosomes were incubated with an excess of 4
mM recombinant PU.1 for 30 min at 30 °C in reaction buffer (20 mM Tris-HCl pH
7.6, 1.5 mM MgCl2, 0.5 mM EGTA, 300 mM KCl, 10% glycerol, 10 mM dithio-
threitol (DTT)). The samples were then resolved on a 0.4× TBE 6% native PAA gel
for 90 min at 4 °C and 130 V. The gels were subsequently scanned on a GE FLA-
9000 instrument.
Microscale thermophoresis measurements. Motif affinity measurements were
essentially carried out as described previously11. In brief, binding assays were
performed using annealed oligonucleotides (Cy3-labeled on one strand, listed in
Supplementary Table 3) and recombinant full-length PU.1 on the Nanotemper
Monolith NT.115 device. The sequence of the full-length hPU.1 was amplified by
PCR from pORF9-hSPI1 (InvivoGen) and recombined into a modified pDM8
vector, encoding an N-terminal His-tag, using the Gateway technology (Life
Technologies). The protein was expressed in Rosetta2(DE)pLysS (Novagen) and
purified by Nickel affinity chromatography (Qiagen) as described above. Analyzed
oligomers were synthesized with Cy3-labeled, with either a methylated or
hydroxyl-methylated CpG-site (5mC/5hmC), or as unmodified DNA oligomers
(Sigma). For each motif, two independent sets of 16 affinity measurement reactions
were prepared using a dilution series of PU.1 protein where the concentration of
the double-stranded oligonucleotide was kept constant (50 nM). Data analysis was
done using the NT-analysis acquisition software (1.2.229).
ChIP-seq library preparation. ChIP was performed in biological replicates as
described previously with slight modifications9. Chromatin for all ChIP-seq
experiments of mRNA-transfected cells was collected 8 h after transfection, besides
for ChIP-seq analyses of PU.1-BirA, ΔA-BirA, and ΔQ-BirA fusion constructs,
which were already collected 5 h after transfection. Briefly, for H3K27ac and PU.1/
FLAG ChIP-seq, cells were crosslinked with 1% formaldehyde for 10 min at room
temperature and the reaction was quenched with glycine at a final concentration of
0.125 M. For SMARCA4/BRG1, ETS1 and FLI1 ChIP-seq experiments dual
crosslinking was performed. Cells were crosslinked first with 2 mM disuccinimidyl
glutarate (Thermo Fisher Scientific) in PBS for 30 min at room temperature.
Subsequently, cells were fixed with 1% formaldehyde for 10 min at room tem-
perature and the reaction was quenched with glycine at a final concentration of
0.125 M.
Chromatin of all ChIP experiments was sheared using sonication (Branson
Sonifier 250) to an average size of 250–500 bp. A total of 2.5 µg of antibody against
H3K27ac (Abcam, ab4729), PU.1 (Santa Cruz, sc-352×), FLAG M2 (Sigma Aldrich,
F3165), ETS1 (Santa Cruz, sc-350×), FLI1 (Abcam, ab15289), or SMARCA4/BRG1
(Abcam, ab110641) was added to sonicated chromatin of 2 × 106 cells and
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incubated overnight at 4 °C. Protein A or G (for FLAG ChIP-seq) sepharose beads
(GE healthcare) were added to the ChIP reactions and incubated for 2 h at 4 °C.
Beads were washed and chromatin was eluted. After crosslink reversal, RNase A
and proteinase K treatment, DNA was extracted with the Monarch PCR & DNA
Cleanup kit (NEB). Sequencing libraries were prepared with the NEBNext Ultra II
DNA Library Prep Kit for Illumina (NEB) according to the manufacturer’s
instructions. The quality of dsDNA libraries was analyzed using the High
Sensitivity D1000 ScreenTape Kit (Agilent) and concentrations were assessed with
the Qubit dsDNA HS Kit (Thermo Fisher Scientific). Libraries were single-end
sequenced on a HiSeq3000 or NextSeq550 (Illumina). Sequencing libraries are
listed in Supplementary Data File 1.
ATAC-seq library preparation. ATAC-seq was essentially carried out as descri-
bed41 8 h after mRNA transfection of CTV-1, HEP-G2, and TALL1 cells. Briefly,
prior to transposition the viability of the cells was assessed and 1 × 106 cells
were treated in culture medium with DNase I (Sigma) at a final concentration of
200 Uml−1 for 30 min at 37 °C. After Dnase I treatment, cells were washed twice
with ice-cold PBS, and cell viability and the corresponding cell count were assessed.
For each ATAC reaction, 5 × 104 cells were aliquoted into a new tube and spun
down at 500 × g for 5 min at 4 °C, before the supernatant was discarded completely.
The cell pellet was resuspended in 50 µl of ATAC-RSB buffer (10 mM Tris-HCl pH
7.4, 10 mM NaCl, 3 mM MgCl2) containing 0.1% NP-40, 0.1% Tween-20, and 1%
digitonin (Promega), and was incubated on ice for 3 min to lyse the cells. Lysis was
washed out with 1 ml of ATAC-RSB buffer containing 0.1% Tween-20. Nuclei were
pelleted at 500 × g for 10 min at 4 °C in a fixed-angle centrifuge. The supernatant
was discarded carefully and the cell pellet was resuspended in 50 µl of transposition
mixture (25 µl 2× tagment DNA buffer, 2.5 µl transposase (100 nM final; Illumina),
16.5 µl PBS, 0.5 µl 1% digitonin, 0.5 µl 10% Tween-20, 5 µl H2O) by pipetting up
and down six times. The reaction was incubated at 37 °C for 30 min with mixing
(1000 r.p.m.) before the DNA was purified using the Monarch PCR & DNA
Cleanup Kit (NEB) according to the manufacturer’s instructions. Purified DNA
was eluted in 20 µl elution buffer (EB) and 10 µl purified sample was objected to a
ten-cycle PCR amplification using Nextera i7- and i5-index primers (Illumina).
Purification and size selection of the amplified DNA were carried out with mag-
netic beads (Agencourt AMPure XP). For purification the ratio of sample to beads
was set to 1:1.8, whereas for size selection the ratio was set to 1:0.55. Purified
samples were eluted in 15 µl of EB. Quality and concentration of the generated
ATAC libraries were analyzed using the High Sensitivity D1000 ScreenTape Kit
(Agilent) and libraries were sequenced paired-end on a NextSeq550 (Illumina).
Sequencing libraries are listed in Supplementary Data File 1.
RNA-seq library preparation. To analyze gene expression profiles of various cell
types under several conditions, e.g., PU.1-transfected vs. PU.1mut-transfected cells,
RNA-seq was performed 24 h after mRNA transfection (short) or after seven cycles
of PU.1 mRNA electroporation over 7 days (long). Generation of dsDNA libraries
for Illumina sequencing from total cellular RNA was carried out using the
ScriptSeq Complete Kit (Illumina). Typically, 1 µg of DNA-free RNA was used for
each reaction. In a first step, rRNA was depleted using the Ribo-Zero rRNA
removal reagents included in the kit. rRNA-free RNA was then converted into
cDNA, 3′-terminal tagged, and was used for PCR amplification and library pur-
ification. The quality of dsDNA libraries was analyzed using the High Sensitivity
D1000 ScreenTape Kit (Agilent) and concentrations were assessed with the Qubit
dsDNA HS Kit (Thermo Fisher Scientific). Paired-end sequencing was carried out
on HiSeq1000 or HiSeq3000 instruments (Illumina). Sequencing libraries are listed
in Supplementary Data File 1.
Proximity-dependent biotinylation assay (BioID). BioID experiments to analyze
proximity-dependent interactions of PU.1 and vincinal proteins were essentially
carried out as described22 with slight modifications to adapt the protocol to our
transient mRNA transfection approach. Each experiment was performed in three
independent biological replicates. Briefly, wild-type PU.1, or its ΔA and ΔQ
deletion mutants, were fused to promiscuous E. coli biotin ligase (BirA*, harboring
a R118G point mutation) via a flexible linker and ordered as gBlock gene fragments
at IDT (sequences are given in Supplementary Data File 2). The biotin ligase fused
to a nuclear localization sequence (NLS) was used as control for all experiments.
Constructs were assembled into a BamHI and XbaI (NEB)-linearized T7 promoter-
containing vector (pEF6; Invitrogen) using the NEBuilder HiFi DNA Assembly
Master Mix (NEB). SfuI (Roche) linearized plasmids were phenol:chloroform-
purified and used to generate IVT mRNA with the mMESSAGE mMACHINE T7
Ultra Kit (Ambion) according to the manufacturer’s instructions. Finally, generated
IVT mRNA was purified with the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. Usually, 100 µg of PU.1-BirA* IVT mRNA was
introduced into 50 × 106 cells using electroporation. IVT mRNA amounts of
additional constructs were calculated according to their protein size relative to
PU.1-BirA* (ΔA-BirA* 90 µg, ΔQ-BirA* 96 µg, or NLS-BirA* 50 µg of IVT
mRNA). Three hours after transfection, the cell culture medium was supplemented
with 50 µM biotin (Sigma) to achieve biotinylation of vicinal proteins. Five hours
after biotin supplementation, cells were collected for subsequent lysis and pur-
ification of biotinylated proteins. The optimal time points for the addition of biotin
and to collect the cells were determined by immunoblotting. Cell pellets were
washed twice with ice-cold PBS to eliminate residual biotin. For lysis, cell pellets
were first swelled in ice-cold lysis buffer 1 A (10 mM Hepes pH 7.5, 85 mM KCl, 1
mM EDTA pH 8.0, 1 mM PMSF, 1 mM Na3VO4, 1× protease inhibitor cocktail),
before an equal amount of ice-cold lysis buffer 1B (10 mM Hepes pH 7.5, 1% NP-
40, 85 mM KCl, 1 mM EDTA pH 8.0, 1 mM PMSF, 1 mM Na3VO4, 1× protease
inhibitor cocktail) was added. Suspensions were incubated on ice for 10 min before
nuclei were spun down at 700 × g for 5 min at 4 °C. In a next step, nuclei were
resuspended in lysis buffer 2 (50 mM Tris-HCl pH 7.4, 0.4% SDS, 5 mM EDTA pH
8.0, 500 mM NaCl, 1 mM PMSF, 1 mM Na3VO4, 1× protease inhibitor cocktail)
and sonicated to shear genomic DNA. All sonication steps were carried out with a
constant duty cycle, output control 2, for 10 s using a Branson Sonifier 250. After
the first sonication, Triton X-100 was added to a final concentration of 2% before
lysates were sonified again. Finally, an equal amount of ice-cold dilution buffer (50
mM Tris-HCl pH 7.4, 1 mM PMSF, 1 mM Na3VO4, 1× protease inhibitor cocktail)
was added and suspensions were sonified one last time. Insoluble materials were
removed by centrifugation, before a dialysis step using Slide-A-Lyzer MINI Dialysis
Devices (Thermo Fisher Scientific) was performed to remove residual biotin o/n at
4 °C. The next day, prewashed Pierce Streptavidin Magnetic Beads (Thermo Fisher
Scientific) were added and lysates were incubated for 2 h on a rotating wheel at
room temperature. Beads were washed three times each with 100 mM NH4HCO3
and 4M Urea in Tris-HCl pH 8.0, respectively. On-bead digestion of captured
protein complexes and subsequent mass spectrometry analysis were carried out in
collaboration with the Protein Analysis Unit at the Biomedical Center (LMU,
Munich, Germany). Beads were resuspended in 40 µl of 100 mM Tris pH 7.6
containing 4M urea and 0.5 µg LysC. The mixture was incubated at 28 °C for 1.5 h
to release bound proteins into the solution. The supernatant was subsequently
transferred into a fresh vial and the beads were washed twice with 100 µl of 100
mM Tris pH 7.6. Both wash fractions were combined with the supernatant and
DTT was added to a final concentration of 10 mM for reduction of disulfide bonds.
Next, 1 µg trypsin was added to proteolytically cleave the oligopeptide mixture at
28 °C for 12 h. Subsequently, 1 M iodoacetamide in 100 mM Tris pH 7.6 was added
to a final concentration of 30 mM to alkylate-free cysteine side chains. After 30 min
incubation at room temperature, the samples were acidified by adding 3 µl of 90%
formic acid (FA) and 10% trifluoroacetic acid. Residual beads were removed with a
magnet and the oligopeptide mixture was a desalted using the C18 stage tip pro-
tocol42. Briefly, three layers of C18 discs (Empore C18, 3 M) were placed in a 200 µl
tip, washed, and samples were loaded onto the column. For sample loading, a low
centrifugation speed of 70 × g was applied until the complete sample was flown
through the column. For salt removal, 3 × 50 µl 0.1% FA were applied with fast
centrifugation at 250 × g. Finally, peptides were eluted with 2 × 60 µl of 70%
acetonitrile (ACN), containing 0.1% FA, subsequently vacuum dried, and recon-
stituted in 10 µl of 0.1% FA in water as loading buffer for the high-performance
liquid chromatography (HPLC) separation.
All samples were analyzed via nano reversed-phase liquid chromatography
tandem mass spectrometry (MS/MS) on the Ultimate 3000 nCS HPLC system
coupled to an QExactive HF mass spectrometer. Samples were loaded onto the
chromatographic column (150 × 0.075 mm, packed in-house with 2.4 µm C18
chromatographic material Reprosil-AQ, Dr Maisch GmBH) by direct injection. For
peptide separation, a linear gradient over 60 min from 4% to 40% ACN in 0.1% FA
was applied. The column outlet was connected to the nano-electrospray ionization
source to transfer the eluting ions directly into the QExactive HF MS for peptide
analysis. The mass spectrometer was operated in data-dependent acquisition mode
acquiring one survey scan covering the range of 350–1600 m z−1 at 60,000
resolution, followed by up to 10 MS/MS scans of selected peptide precursors per
cycle. Suitable precursors had a defined charge state between 2 to 5+, a minimal
intensity of 4.0 e4, and were isolated with in a 1.5 Da window. Peptide precursors
were fragmented in the higher-energy collisional dissociation cell applying a
normalized collision energy of 27 and spectra were acquired in the orbitrap at
15,000 res. To prevent repeated analysis of precursors, dynamic exclusion was
programmed for 15 s with a 12 p.p.m. window around the signal of previously
fragmented precursors. A list of all processed samples is provided in
Supplementary Table 4.
Detection of biotinylated proteins in whole-cell lysates. To analyze the global
biotinylation upon transfection with various mRNAs, CTV-1 cells were transfected
as described above. Three hours after transfection, the transfected cells were sup-
plemented with 50 µM biotin or not and cells were collected and lysed 5 h after
biotinylation. Whole-cell lysates were separated by SDS-PAGE and were blotted as
described above. Membranes were blocked in 1% BSA in PBS with 0.2% Triton X-
100 and incubated in the same buffer with horseradish peroxidase-conjugated
streptavidin (ab7403, Abcam, 1:10,000) overnight. After three quick washes with
PBS, membranes were agitated for 5 min in 10% BSA in PBS with 1% Triton X-100
and biotinylated proteins were detected after three additional washes with PBS.
BRG1 inhibition assay. The small molecule inhibitor PFI-3 (Sigma) was used to
selectively inhibit the SMARCA4/2 polybromo 1 domain of the SWI/SNF complex.
PU.1 IVT mRNA-transfected CTV-1 cells were cultured in RPMI 1640 medium
(Gibco) supplemented with 10% FCS (Gibco) containing the indicated amounts of
the small molecule inhibitor PFI-3. Eight hours after transfection and
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corresponding treatment, cells were collected and were used for subsequent ChIP-
seq analysis as described above, using the anti-FLAG M2 antibody (Sigma) to
analyze PU.1 binding patterns in the heterologous cell type upon inhibition of the
SMARCA4/2 component of the SWI/SNF complex.
RNA-seq analysis. Sequencing reads were mapped to the human genome using
STAR v2.5.3a43. The human hg19 genome index together with gene annotation
from GENCODE44 (release 19) was used to aid in spliced alignment. Tables of raw
uniquely mapped read counts per human gene were generated during mapping
using the built-in --quantMode GeneCounts option in STAR. For the comparison
of gene expression levels between ETS family factors shown in Fig. 2c, relative
expression data were corrected for transcript length and were plotted for selected
genes using the ggplot2 (v3.1.0) package in R 3.4.3. Differential expression analysis
was carried out on raw gene counts using edgeR 3.20.845 in R, comparing PU.1
mRNA-transfected cells with control cells transfected with a mutant PU.1 mRNA,
focusing on genes with an absolute fold change > 2 and a false discovery rate
(FDR) < 0.05. The volcano plot of the edgeR results in Fig. 2e was generated using
the ggplot2 package in R. Statistically significant enriched GO terms were identified
using Metascape46 and the GO-term network graph in Fig. 2f was rearranged using
Cytoscape47. To compare the expression of differentially regulated genes with the
SPI1 gene expression across various cell lineages (as shown in Fig. 2g), we extracted
Cap Analysis of Gene Expression data provided by the FANTOM consortium35
and plotted the data using the ggplot2, reshape, and ggrepel packages in R. To
calculate significance levels for Pearson’s correlations shown in Fig. 2g, we used the
rcorr() function in the Hmisc package in R. Correlation coefficient and significance
shown in Supplementary Fig. 4b were calculated using the stat_cor function in the
ggpubr package in R.
ChIP-seq analysis. Reads (single-end) were aligned to the human genome
(GRCh37/hg19) using bowtie248 in a very sensitive mode, keeping only reads that
map to a single unique genomic location for further analysis (MAPQ > 10). Initial
quality control was performed by calculating the fraction of reads in peaks (FRIP,
summarized in Supplementary Table 1 and Data File 1) by running HOMER’s8
(v4.9) findPeaks program in “factor” or “histone” mode using default parameters
and the appropriate matching background dataset (either ChIP input, genomic
DNA, or control ChIP). For further analyses, chromosome scaffolds were removed.
For cancer cell lines, we used the Control-FREEC v11.0 program49 to determine
allelic imbalances from low-depth whole genome sequencing data and corrected
ChIP-seq read counts accordingly. ChIP-seq peaks were called using HOMER’s
findPeaks program in “factor” mode using default parameters (standard) or with
-fdr 0.00001 (stringent) to identify focal peaks. Stringent peaks were further filtered
for a minimal normalized tag count of 15 tags per peak. All peak sets were filtered
by subtracting blacklisted genomic regions50 and by filtering out regions with a
mappability < 0.8. The latter was annotated to peak regions from mappability
tracks generated with the GEM package51 using HOMER’s annotatePeaks.pl.
Overlapping peak locations across multiple cell types were identified using the
HOMER mergePeaks program, which was also used to count the frequency of each
peak being called across cell types, and to determine unique (cell type-specific)
peaks, e.g., as used in Supplementary Fig. 1b. To study the relationships between
ChIP-seq samples, reads in peaks (200 bp) from individual samples were counted
across merged peak sets using the HOMER annotatePeaks program. Normalization
was done utilizing the rlog function of DESeq252. Dimensionality reduction based
on the tSNE algorithm (Fig. 7d and Supplementary Fig. 1a) was done using the
Rtsne package and visualized using the ggplot2 package in R. The heatmap of
normalized and scaled read counts across unique peaks (Supplementary Fig. 1b)
was plotted in R.
To structure the PU.1 peak sets obtained after PU.1 mRNA transfection based
on chromatin accessibility, we used the kmeans function in R to cluster ATAC read
counts in 300 bp peak-centered windows of PU.1-transfected and control-
transfected cells. Clusters were ordered to reflect increasing accessibility (as shown
in Fig. 3). To assign genes to peaks in individual clusters, we identified associations
in a stepwise process. First, TSSs (transcription start sites; derived from GENCODE
release 19 transcripts) for expressed genes (as determined from RNA-seq data)
were determined. Second, every gene was assigned to a regulatory domain as
follows: each gene is assigned a basal regulatory domain of 25 kb upstream and
downstream of the TSS (regardless of other nearby genes). Next, the gene
regulatory domain is extended in both directions to the nearest gene’s basal domain
but no more than 250 kb in one direction. Then, each genomic region is associated
either with a gene, if it is close to its promoter (within 1000 bp distance to a TSS),
or if promoter distal, the region is checked for overlaps with GTEx expression
quantitative trait loci (eQTL) SNPs (single-nucleotide polymorphisms; from whole
blood, release 7). When within a 1000 bp distance to an eQTL, all genes associated
with the SNP are assigned to this region. If there is no overlap with either TSS or
eQTL, regions are associated with all genes whose regulatory domain they overlaps.
To determine whether the expression of genes associated with individual peak
clusters was significantly upregulated, we compared their RNA-seq gene expression
data in R using a paired Wilcoxon’s test (as indicated in Fig. 3).
Read coverage across individual peaks sets (as shown in Figs. 3, 6e, 8g or
Supplementary Fig. 3b) was calculated using HOMER’s annotatePeaks.pl with
parameters “-hist 25 -ghist” using merged replicate ChIP-seq data sets and plotted
in R using the image function.
Positions of PU.1 peaks relative to genes (Fig. 4e) were extracted using
HOMER’s annotatePeaks program based on gene annotation from GENCODE
(release 19). The corresponding stacked bar chart was generated in R using the
ggplot2 package.
Statistically significant differences in read counts across peaks between sets of
ChIP-seq experiments were determined using HOMER’s
getDifferentialPeaksReplicates.pl, which utilizes statistical modeling functions of
DESeq2. ChIP-seq coverage across peak sets was determined using the -hist option
of HOMER’s annotatePeaks.pl and “-hist 25 -ghist”. Average coverage data and
95% confidence intervals were then calculated in R and the ggplot2 package was
used to draw histograms (Supplementary Figs. 4e, f, 5a, b, d, h, and 6j).
To generate scatter plots comparing ChIP-seq data for BirA- and control
constructs across a common peak set (Supplementary Fig. 6c), reads were counted
using HOMER’s annotatePeaks program. Scatter plots were drawn in R using the
ggplot2 package and corresponding correlation coefficients were calculated in R.
Overlaps between PU.1 and ETS factor peaks (Fig. 6f and Supplementary
Fig. 5c) were determined using bedtools’ intersect program53 and corresponding
bar charts of peak fractions were drawn in R using the barplot function.
Plots illustrating the abundance of differential peak sets across clustered peaks
(Fig. 7e) were generated in R using the image function.
ATAC-seq analysis. Reads (paired-end) were aligned to the human genome
(GRCh37/hg19) using bowtie2 in very sensitive and no-discordant modes, keeping
only reads that map to a single unique genomic location for further analysis
(MAPQ > 10). Read positions were adjusted to move the ends proximal to the Tn5-
binding site (for reads on the positive strand, the start is shifted +4 bp and its
partner reads start −5 bp; for reads on the negative strand, the start is shifted −5
bp and its partner reads start +4 bp). Initial quality control was perfomed by
calculating the FRIP (summarized in Supplementary Data File 1) by running
HOMER’s findPeaks program in using parameters “-region -size 150”. We used the
Control-FREEC 11.0 program to determine allelic imbalances from low-depth
whole genome sequencing data and corrected ATAC-seq read counts accordingly.
ATAC-seq peak regions were called by combining two different approaches: the
basic peak region set was called using HOMER’s findPeaks program in “region”
mode using parameters “-size 150 -minDist 250 -L 2 -fdr 0.00001” to identify
regions of variable length by stitching nucleosome-size peaks. To exclude shallow
peak regions, only those were kept that overlapped a second peak set that was
generated in “factor” mode using parameters “-size 250 -minDist 250 -L 2 -fdr
0.00001” to identify focal peaks. Statistically significant differences in read counts
across peaks between sets of ATAC-seq experiments were determined using
HOMER’s getDifferentialPeaksReplicates.pl.
Read coverage across individual peaks sets (as shown in Figs. 3, 6e, 8g or
Supplementary Fig. 3b) was calculated using HOMER’s annotatePeaks.pl with
parameters “-hist 25 -ghist” using merged replicate ATAC-seq data sets and plotted
in R using the image function.
Motif analysis. The consensus motif for PU.1 was originally described in Pham
et al.9. To determine all 12-mers across the genome overlapping the PU.1 con-
sensus sequence, we used HOMER’s8 scanMotifGenomeWide program. All motif
locations were then filtered for blacklisted genomic regions50, extended to 200 bp
regions, and filtered for mappability, equivalent to ChIP-seq peaks. Overlaps
between motif-matching sequences and peak regions were determined using the
bedtools’ intersect program. Motif regions with no evidence of ChIP-seq signal
(unbound) were determined by annotating normalized PU.1 ChIP-seq reads across
all available natively PU.1-expressing cell types using HOMER’s annotatePeaks.pl
and those with read counts > 3 in any sample were removed. Venn diagrams for
overlapping motif or peak region sets (Figs. 1b and 6d) were drawn in R using the
venneuler package. Motif log odds scores for PU.1 motif- or other motif-
overlapping sequences in motif or peak region sets were calculated using HOMER’s
annotatePeaks program. Distributions of motif scores (as shown in Figs. 1c, 4a, and
6g, and Supplementary Figs. 1b, e, 3e, and 5e) were visualized using the beanplot
package in R.
De novo motif discovery in peaks or regions (e.g., as shown in Figs. 4b, 5a, and
6b, and Supplementary Figs. 2b, 3c, d, h, j, and 5a, b) was performed with
HOMER’s findMotifsGenome program and parameters “-len 7,8,9,10,11,12,13,14
-h”. For searches in ChIP-seq peaks we used a 200 bp peak-centered window,
whereas for differential ATAC regions the given region sizes were used. De novo
motifs were further filtered using HOMER’s compareMotifs.pl and parameters
“-reduceThresh .75 -matchThresh .6 -pvalue 1e-12 -info 1.5”. For motif searches
across all ATAC peak regions, we reduced the search space by focussing on Tn5
integration sites. Here, “small” peaks were called in “region” mode using
parameters “-size 12 -fragLength 1 -minDist 16 -L 0”. These small focussed ATAC
regions were then intersected with the original ATAC region set, extended by 48 bp
on each side, merged and finally reduced by 24 bp on each side using the program
suite bedtools.
To compare motif enrichment across different cell types or peak clusters, de
novo motifs derived from unique or clustered peak sets were combined and filtered
using HOMER’s compareMotifs program and parameters “-reduceThresh .75
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-matchThresh .6 -pvalue 1e-12 -info 1.5”, keeping only motifs that matched known
motifs with a correlation > 0.85. Filtered de novo motifs (e.g., as in Fig. 4b) were
then annotated back to each peak set using HOMER’s findMotifsGenome.pl using
parameters “-size 200 -mknown -nomotif -h”, and results were visualized in R
using the ggballoonplot function of the ggplot2 package where balloon size
corresponds to motif enrichment and corresponding P values are color coded (as in
Supplementary Figs. 1c, 2c, and 3c, d).
To determine peak-wise motif co-association we first performed a known motif
search using HOMER’s findMotifsGenome.pl across unique or clustered peak sets
with the PU.1 motif masked and determined the list of known motifs overlapping
the previously determined de novo motif classes (e.g., Ebox, GATA, or RUNX). All
listed motifs (except PU.1) were then counted in peak regions using HOMER’s
annotatePeaks.pl with parameters “-m known.motifs -fm PU1motif -matrixMinDist
4 -nogene -noann -nmotifs”. Motif overlap in each individual peak was then
reduced to motif class overlap (using the filtered known motif list), which was
counted as positive for a particular class, if one of the class matching known motifs
was present, or negative, if none was present. To count PU.1 motifs in peaks, we
used HOMER’s annotatePeaks program with parameters “-m PU1motif
-matrixMinDist 6 -nogene -noann -nmotifs”. The combined count table was then
used to generate a motif co-occurrence matrix and to calculate node sizes and edges
width (each represented as % of all peaks). Networks of motif co-association were
generated in R using the igraph package (as shown in Fig. 4c and Supplementary
Fig. 1d). To improve the visualization, colors of individual nodes were edited in
Adobe Illustrator.
Footprints across motif-centered peak sets (centered using HOMER’s
annotatePeaks.pl programm) were generated using the -hist option of HOMER’s
annotatePeaks.pl with parameters “-hist 1 -len 1” and plotted in R using the
ggplot2 package (as shown in Figs. 4g and 5b–d, and Supplementary Fig. 3i, k).
To study the evolutionary conservation of PU.1 motifs in clusters, PhastCons
scores were annotated to PU.1 motif-centered cluster peaks, as well as matching
random unbound control motifs with HOMER’s annotatePeaks program using the
hg19.100way.phastCons.bw file from the UCSC Genome browser. To reduce bias
for low-affinity motifs, matching random unbound control motifs were generated
for each of the 14 Kmeans clusters by extracting the frequency of each nucleotide
sequence (“word”) in each cluster using the homerTools program and randomly
selecting the same number (if available) of each word from the set of motif regions
with no evidence of ChIP-seq signal (defined as max. normalized read count of one
in a motif-centered 200 bp window).
To study the relationship between DNA methylation at the GGAA-proximal
CpG (CGGAA), which was shown to inhibit PU.1 binding in microscale
thermophoresis assays, we utilized published DNA methylation data for HepG2
cells (GEO acc. GSM1204463). We extracted positions of all sequences covered by
the consensus PU.1 motif that contained a GGAA-proximal CpG motif (20846 of
1.88 × 106 mappability-filtered PU.1 recognition sequences) using homerTools’
extract function, removed paired motifs (were ChIP-seq signals may derive from a
neighboring PU.1 motif lacking the proximal CpG), and annotated the remaining
sequences (or the subset overlapping stringent HepG2 peaks) with the available
DNA methylation data. Distributions of DNA methylation ratios (as shown in
Supplementary Fig. 3g) were visualized using the beanplot package in R.
Homotypic PU.1 motif pairs with a max. distance of 150 bp were initially
determined from all motif occurences, keeping orientation, distance and motif
scores of each motif in each pairing. To determine whether there is a preferred
distance/orientation of motifs, pairs were overlapped with PU.1 peaks to separate
pairs into bound and unbound fractions, which were further divided into pairs with
motifs in the same (sense-sense) or opposite orientations (sense–antisense).
Significant enrichment (hypergeometric P < 0.05) of a particular motif distance was
calculated in R using the phyper function. Distance frequencies of bound and
unbound pairs in the same or opposite orientations were plotted in R using the
ggplot package and significantly enriched distances were marked by orange color
(Supplementary Fig. 4a). As the range of 12–50 bp was significantly
overrepresented in the bound fraction, further analyses were focused on pairs in
this range. Non-paired (single) motifs were defined as lacking a neighboring PU.1
motif within a 150 bp distance. Paired or single motif region sets were further
divided into ETS-bound or ETS non-bound motifs using bedtools’ intersect
program. Plots illustrating the abundance of paired or single motifs across clustered
peaks (Supplementary Figs. 4d and 5f) were generated in R using the image
function.
Generation of read coverage tracks. HOMER was used to generate sequencing-
depth normalized bedGraph/bigWig files of ChIP-seq and ATAC-seq data (using
standard parameters for ChIP and a fixed fragment length of 65 bp for ATAC).
BedGraph/bigWig files of RNA-seq data were generated during alignment using
the “--outWigType bedGraph” option of STAR. BigWigs from replicate data sets
were averaged using the program bigWigMerge54 and dividing the count data by
the number of sample. Resulting bedGraph files were converted to BigWig using
the program bedGraphToBigWig54. Tracks were visualized using the IGV
browser55. Selected regions (as shown in Figs. 1a, 2d, 6a, 7c, and 8f, and Sup-
plementary Figs. 3a and 6b, i) were exported in svg format and formatted in
Adobe Illustrator.
Binding site prediction. To predict which PU.1 motifs are bound in a given cell
type, we modeled the probability of a peak (as defined using HOMER’s findPeaks
program in “factor” mode with parameter “-fdr 0.00001” to focus on stringent
peaks) by multiple logistic models with different sets of predictor variables. These
included motif log odds scores (annotated using HOMER’s annotatePeaks.pl
program with parameters “-m PU1motif -mscore”), conservation of motifs pro-
vided as average PhastCons scores (annotated with HOMER’s annotatePeaks.pl
program using the hg19.100way.phastCons.bw file from the UCSC Genome
browser), chromatin accessibility before and after PU.1 induction (represented by
ATAC-seq signals annotated into 50 bp, motif-centered regions using HOMER’s
annotatePeaks.pl program with parameter -len 1), and neighboring motifs of
putative co-associated factors (initially determined by de novo motif searches in
ATAC-seq regions of control cells performed with HOMER’s findMotifsGenome
program and parameters “-len 7,8,9,10,11,12,13,14 -h”, filtered using HOMER’s
compareMotifs program and parameters “-reduceThresh .75 -matchThresh .6
-pvalue 1e-12 -info 1.5”, keeping only motifs that matched known motifs with a
correlation > 0.85). Neighboring motifs were represented by binary variables,
indicating their presence between 6 bp and 100 bp from the center of the PU.1
motif. Higher-order interaction terms of these variables were not found to improve
predictivity.
We trained the logistic models on a randomly selected half of all candidate
sites and evaluated their predictivity on the remaining half by their receiver
operating characteristic (ROC) curves and corresponding areas under the
curve using the pROC package in R, as shown in Fig. 4f and Supplementary
Fig. 3f.
MS data analysis. MS data were searched in the MaxQuant software suite
(1.6.0.16) against the human database (Uniprot, 02/2015) using the andromeda
search algorithm and finally filtered for a FDR of 5% on protein level and 2% on
the level of peptide-to-spectrum matches. The iBAQ quantification option was
enabled and peptide modifications of methionine (oxidation, variable), cysteine
(carbamidomethylation, fixed), and protein N-terminus (acetylation) were selected.
For further statistical analysis of the proteomics data, iBAQ values were log2
transformed, median normalized, and all proteins with less than two valid values in
all experimental conditions were filtered out. Missing values in the residual dataset
were filled up with random values from a Gaussian distribution with downshift of
1.9 and width of 0.3 to simulate noise using the Perseus software suite (version
1.5.5.3 for THP-1 and 1.5.8.2 for K-562 and CTV-1 cells). Subsequently, experi-
mental groups of background control (NLS-BirA) and TF BioIDs (PU.1-BirA, ΔQ-
BirA, or ΔA-BirA) were compared via two-sided Student’s t-test with a
permutation-based FDR rate correction of 5%. For this comparison, the Null
hypothesis s0 was set to 0.5 and the number of permutations was set to 250.
Statistically enriched proteins were further subjected to GO-term analysis using the
gene annotation and analysis resource Metascape. Protein networks shown in
Fig. 8c were visualized using the STRING network app in Cytoscape 3.6.1. The
volcano plot (Fig. 8b) was drawn in R using ggplot2 and ggrepel packages. Dot
plots shown in in Fig. 8d and Supplementary Fig. 6d were drawn in R using ggplot2
and grid packages.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The GEO accession number for the NGS raw data and processed data files (bigwig tracks,
peak files) is GSE128837. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE56 partner repository with the dataset
identifier PXD013167. All other relevant data supporting the key findings of this study
are available within the article and its Supplementary Information files or from the
corresponding author upon reasonable request. The source data underlying Figs. 1a–c,
2b, c, e–g, 3, 4a–g, 5a–d, 6b–g, 7b–e, and 8b–e, g, and Supplementary Figs. 1a–d, 2a–c,
3b–k, 4a-g, 5b–h, and 6a, c–h, j are provided as a Source Data file. A reporting summary
for this article is available as a Supplementary Information file.
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No new analysis software was developed for this study. Code required to reproduce the
results discussed herein are available upon request.
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